{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:38:19Z","timestamp":1792726699394,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cardiothorac Surg"],"DOI":"10.1186\/s13019-026-04572-1","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:14:29Z","timestamp":1785251669000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["SGLT2 inhibitor therapy following aortic valve intervention for aortic stenosis: a systematic review and meta-analysis of mortality, heart failure, rhythm, renal, and valve-related outcomes"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1926-3535","authenticated-orcid":false,"given":"Hamzah Pratama","family":"Megantara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iwan","family":"Dakota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taofan","family":"Taofan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suci","family":"Indrian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth Grace","family":"Aurora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suko","family":"Adiarto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"issue":"11","key":"4572_CR1","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.jacc.2013.05.015","volume":"62","author":"RLJ Osnabrugge","year":"2013","unstructured":"Osnabrugge RLJ, Mylotte D, Head SJ, et al. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study. J Am Coll Cardiol. 2013;62(11):1002\u201312. https:\/\/doi.org\/10.1016\/j.jacc.2013.05.015.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"4572_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/eurheartj\/ehab395","volume":"43","author":"A Vahanian","year":"2022","unstructured":"Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC\/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43(7):561\u2013632. https:\/\/doi.org\/10.1093\/eurheartj\/ehab395.","journal-title":"Eur Heart J"},{"issue":"4","key":"4572_CR3","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.jacc.2020.11.018","volume":"77","author":"CM Otto","year":"2021","unstructured":"Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC\/AHA guideline for the management of patients with valvular heart disease. J Am Coll Cardiol. 2021;77(4):e25\u2013197. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.018.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"4572_CR4","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.jcin.2024.02.011","volume":"17","author":"M Nakase","year":"2024","unstructured":"Nakase M, Tomii D, Heg D, et al. Long-term impact of cardiac damage following transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2024;17(8):992\u20131003. https:\/\/doi.org\/10.1016\/j.jcin.2024.02.011.","journal-title":"JACC Cardiovasc Interv"},{"issue":"10166","key":"4572_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis. Lancet. 2019;393(10166):31\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(18)32590-X.","journal-title":"Lancet"},{"issue":"10","key":"4572_CR6","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108\u201317. https:\/\/doi.org\/10.1007\/s00125-018-4670-7.","journal-title":"Diabetologia"},{"issue":"4","key":"4572_CR7","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3390\/ijms26041670","volume":"26","author":"EY Rykova","year":"2025","unstructured":"Rykova EY, Klimontov VV, Shmakova E, Korbut AI, Merkulova TI, Kzhyshkowska J. Anti-inflammatory effects of SGLT2 inhibitors: focus on macrophages. Int J Mol Sci. 2025;26(4):1670. https:\/\/doi.org\/10.3390\/ijms26041670.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"4572_CR8","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa2500366","volume":"392","author":"S Raposeiras-Roubin","year":"2025","unstructured":"Raposeiras-Roubin S, Amat-Santos IJ, Rossello X, et al. Dapagliflozin in patients undergoing transcatheter aortic-valve implantation. N Engl J Med. 2025;392(14):1396\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa2500366.","journal-title":"N Engl J Med"},{"issue":"1","key":"4572_CR9","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s12933-024-02504-8","volume":"23","author":"P Paolisso","year":"2024","unstructured":"Paolisso P, Belmonte M, Gallinoro E, et al. SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI). Cardiovasc Diabetol. 2024;23(1):420. https:\/\/doi.org\/10.1186\/s12933-024-02504-8.","journal-title":"Cardiovasc Diabetol"},{"key":"4572_CR10","doi-asserted-by":"publisher","unstructured":"Obeidat O, Alayyat A, Naser A et al. Impact of SGLT2 inhibitors on long-term outcomes in TAVI patients with heart failure: a propensity-matched analysis. Rev Esp Cardiol (Engl Ed). Published online 2025. https:\/\/doi.org\/10.1016\/j.rec.2025.10.016","DOI":"10.1016\/j.rec.2025.10.016"},{"key":"4572_CR11","doi-asserted-by":"publisher","first-page":"102462","DOI":"10.1016\/j.jacadv.2025.102462","volume":"5","author":"F Yasmin","year":"2026","unstructured":"Yasmin F, Hamza M, Fahim MAA, Asghar MS, Ullah W, Alraies MC. Sodium glucose co-transporter 2 inhibitors in patients with heart failure and transcatheter aortic valve replacement. JACC Adv. 2026;5:102462. https:\/\/doi.org\/10.1016\/j.jacadv.2025.102462.","journal-title":"JACC Adv"},{"key":"4572_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.amjcard.2026.02.043","volume":"266","author":"AM Fahoury","year":"2026","unstructured":"Fahoury AM, Kamel-Abusalha L, Didier AJ, et al. Association of GLP-1 receptor agonist and SGLT2 inhibitor with cardiovascular outcomes after transcatheter aortic valve replacement. Am J Cardiol. 2026;266:99\u2013103. https:\/\/doi.org\/10.1016\/j.amjcard.2026.02.043.","journal-title":"Am J Cardiol"},{"key":"4572_CR13","doi-asserted-by":"publisher","first-page":"100764","DOI":"10.1016\/j.shj.2025.100764","volume":"10","author":"S Zahid","year":"2026","unstructured":"Zahid S, Ahmad M, Salman F, Zahr F, Golwala H. Impact of sodium-glucose cotransporter 2 inhibitors on outcomes after transcatheter aortic valve replacement: a real-world propensity-matched analysis. Struct Heart. 2026;10:100764. https:\/\/doi.org\/10.1016\/j.shj.2025.100764.","journal-title":"Struct Heart"},{"key":"4572_CR14","doi-asserted-by":"publisher","first-page":"1799940","DOI":"10.3389\/fcvm.2026.1799940","volume":"13","author":"B Keskin","year":"2026","unstructured":"Keskin B, Hakgor A, Khidolda Y, et al. Sodium-glucose cotransporter-2 inhibitor use is associated with reduced acute kidney injury after transcatheter aortic valve implantation. Front Cardiovasc Med. 2026;13:1799940. https:\/\/doi.org\/10.3389\/fcvm.2026.1799940.","journal-title":"Front Cardiovasc Med"},{"key":"4572_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3390\/medicina62030535","volume":"62","author":"B Keskin","year":"2026","unstructured":"Keskin B, Hakgor A, Khidolda Y, et al. SGLT2 inhibitor therapy and long-term outcomes after transcatheter aortic valve implantation in patients with low ejection fraction. Medicina. 2026;62:535. https:\/\/doi.org\/10.3390\/medicina62030535.","journal-title":"Medicina"},{"key":"4572_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2026.02.037","author":"X Jacquelyn","year":"2026","unstructured":"Jacquelyn X, Hasan I, Ogami T, et al. Sodium-glucose cotransporter 2 inhibitor use and outcomes after surgical aortic valve replacement. J Thorac Cardiovasc Surg. 2026. https:\/\/doi.org\/10.1016\/j.jtcvs.2026.02.037.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"4572_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s43057-026-00193-5","volume":"34","author":"J Yan","year":"2026","unstructured":"Yan J, McKinnerney J, Al Janabi T, Korgaonkar N, Kashyap R. Initiation of peri-operative SGLT2 inhibitor reduces mortality and cardiovascular events after surgical aortic valve replacement. Cardiothorac Surgeon. 2026;34:9. https:\/\/doi.org\/10.1186\/s43057-026-00193-5.","journal-title":"Cardiothorac Surgeon"},{"issue":"2","key":"4572_CR18","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3390\/jcm15020714","volume":"15","author":"O Morel","year":"2026","unstructured":"Morel O, Guglieri M, Trimaille A, et al. Assessing potential valve-preserving effects of SGLT2 inhibitors in degenerative aortic stenosis: a propensity-matched study. J Clin Med. 2026;15(2):714. https:\/\/doi.org\/10.3390\/jcm15020714.","journal-title":"J Clin Med"},{"key":"4572_CR19","doi-asserted-by":"publisher","unstructured":"Abbas MT, Awad K, Farina JM, et al. The association between sodium-glucose cotransporter 2 inhibitors and bioprosthetic aortic valve degeneration. JACC Adv. 2025;4(5). https:\/\/doi.org\/10.1016\/j.jacadv.2025.101750.","DOI":"10.1016\/j.jacadv.2025.101750"},{"key":"4572_CR20","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"4572_CR21","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomized trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"4572_CR22","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomized studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"key":"4572_CR23","unstructured":"Wells GA, Shea B, OConnell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute. 2011. Available from: https:\/\/ohri.ca\/en\/who-we-are\/core-facilities-and-platforms\/ottawa-methods-centre\/newcastle-ottawa-scale."},{"key":"4572_CR24","unstructured":"Schunemann H, Brozek J, Guyatt G, Oxman A, editors. GRADE Handbook. Version 3.2. Hamilton (ON). GRADE Working Group; 2023."},{"key":"4572_CR25","doi-asserted-by":"publisher","first-page":"e70184","DOI":"10.1002\/edm2.70184","volume":"9","author":"SM Daniyal","year":"2026","unstructured":"Daniyal SM, Khatoon NM, Rasool A, et al. Efficacy of SGLT2 inhibitors on clinical outcomes after transcatheter aortic valve replacement: a systematic review and meta-analysis. Endocrinol Diabetes Metab. 2026;9:e70184. https:\/\/doi.org\/10.1002\/edm2.70184.","journal-title":"Endocrinol Diabetes Metab"},{"key":"4572_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000001150","author":"H Jain","year":"2025","unstructured":"Jain H, Soni K, Jain J, Goyal A, Passey S, Goldsweig AM. Sodium-glucose cotransporter-2 inhibitors following transcatheter aortic valve replacement: a meta-analysis. Cardiol Rev Published online. 2025. https:\/\/doi.org\/10.1097\/CRD.0000000000001150.","journal-title":"Cardiol Rev Published online"},{"issue":"14","key":"4572_CR27","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2020.1906","volume":"323","author":"MC Petrie","year":"2020","unstructured":"Petrie MC, Verma S, Docherty KF, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323(14):1353\u201368. https:\/\/doi.org\/10.1001\/jama.2020.1906.","journal-title":"JAMA"},{"issue":"16","key":"4572_CR28","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2107038.","journal-title":"N Engl J Med"},{"issue":"10254","key":"4572_CR29","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(20)31824-9.","journal-title":"Lancet"},{"issue":"5","key":"4572_CR30","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1007\/s12265-022-10220-5","volume":"15","author":"HM Salah","year":"2022","unstructured":"Salah HM, Verma S, Santos-Gallego CG, et al. Sodium-glucose cotransporter 2 inhibitors and cardiac remodeling. J Cardiovasc Transl Res. 2022;15(5):944\u201356. https:\/\/doi.org\/10.1007\/s12265-022-10220-5.","journal-title":"J Cardiovasc Transl Res"},{"issue":"18","key":"4572_CR31","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","volume":"146","author":"M Packer","year":"2022","unstructured":"Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis. Circulation. 2022;146(18):1383\u2013405. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.061732.","journal-title":"Circulation"},{"issue":"1","key":"4572_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li C, Zhang J, Xue M, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol. 2019;18(1):15. https:\/\/doi.org\/10.1186\/s12933-019-0816-2.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"4572_CR33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1001\/jamasurg.2024.7082","volume":"160","author":"AA Dixit","year":"2025","unstructured":"Dixit AA, Bateman BT, Hawn MT, Odden MC, Sun EC. Preoperative SGLT2 inhibitor use and postoperative diabetic ketoacidosis. JAMA Surg. 2025;160(4):423\u201330. https:\/\/doi.org\/10.1001\/jamasurg.2024.7082.","journal-title":"JAMA Surg"},{"issue":"1","key":"4572_CR34","first-page":"1","volume":"23","author":"BM Bonora","year":"2020","unstructured":"Bonora BM, Avogaro A, Fadini GP. Euglycemic ketoacidosis. Curr Diab Rep. 2020;23(1):1\u201312.","journal-title":"Curr Diab Rep"},{"issue":"1","key":"4572_CR35","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41467-019-08466-w","volume":"10","author":"RJ Perry","year":"2019","unstructured":"Perry RJ, Rabin-Court A, Song JD, et al. Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats. Nat Commun. 2019;10(1):548. https:\/\/doi.org\/10.1038\/s41467-019-08466-w.","journal-title":"Nat Commun"},{"key":"4572_CR36","doi-asserted-by":"publisher","first-page":"200575","DOI":"10.1016\/j.ijcrp.2026.200575","volume":"29","author":"HA Abdul-Hafez","year":"2026","unstructured":"Abdul-Hafez HA, Awashra A, Ahmad M, et al. Colchicine therapy in transcatheter aortic valve replacement: modulating inflammation and outcomes. Int J Cardiol Cardiovasc Risk Prev. 2026;29:200575. https:\/\/doi.org\/10.1016\/j.ijcrp.2026.200575.","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"issue":"1","key":"4572_CR37","doi-asserted-by":"publisher","first-page":"e70152","DOI":"10.1002\/edm2.70152","volume":"9","author":"HA Abdul-Hafez","year":"2026","unstructured":"Abdul-Hafez HA, Awashra A, Bdir S, et al. Tirzepatide and cardiovascular outcomes: a narrative review of mechanisms, efficacy and implications for heart failure management. Endocrinol Diabetes Metab. 2026;9(1):e70152. https:\/\/doi.org\/10.1002\/edm2.70152.","journal-title":"Endocrinol Diabetes Metab"}],"container-title":["Journal of Cardiothoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13019-026-04572-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-026-04572-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13019-026-04572-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:58:48Z","timestamp":1792724328000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13019-026-04572-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4572"],"URL":"https:\/\/doi.org\/10.1186\/s13019-026-04572-1","relation":{},"ISSN":["1749-8090"],"issn-type":[{"value":"1749-8090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"9 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable, as this was a systematic review of previously published aggregated data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"838"}}